Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Selskabsmeddelelse

BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

Oncoinvent
Download udgivelse

Bergen 30 May 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the "Company") earlier today, 30 May 2023, regarding the commencement of the subscription period in the rights issue (the "Rights Issue"). As part of this process, subscription rights have been allocated to primary insiders and their close associates.

Martin Olin, CEO of BerGenBio ASA, has on 30 May 2023 acquired 1 046 125 subscription rights in BerGenBio ASA with no price payable.

Anders Tullgren, Chairman of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 1 409 872 subscription rights in BerGenBio ASA with no price payable.

Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 83 182 subscription rights in BerGenBio ASA with no price payable.

Svev AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 2 945 053 subscription rights in BerGenBio ASA with no price payable.

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 59 719 358 subscription rights in BerGenBio ASA with no price payable.

Sarsia Development AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 33 131 992 subscription rights in BerGenBio ASA with no price payable.

Please see the attached notifications of trade for information regarding the primary insiders' and their close associates' receipt of subscription rights in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.